Chimeric HPV39 L1 Protein for Multi-Type Neutralizing Antibody Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV vaccines have limited protection range, as they primarily induce neutralizing antibodies against a single HPV type, offering low cross-protection against other HPV types, necessitating the inclusion of multiple HPV types in vaccines to broaden protection, which increases production costs and potential safety concerns.
Innovation Solution
A mutated HPV39 L1 protein with specific segment substitutions from HPV68 and HPV70 proteins is developed, inducing high-titer neutralizing antibodies against multiple HPV types, providing protection comparable to a mixture of VLPs from individual HPV types at a reduced immunizing dose.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple HPV types are included in vaccines to broaden protection range, then the protection range is improved, but production cost and device complexity increase
Solution Approach 1:
The patent creates a chimeric L1 protein that combines epitopes from multiple HPV types (HPV39, HPV68, HPV70) into a single protein sequence. This single chimeric protein can induce neutralizing antibodies against multiple HPV types simultaneously, making one vaccine component perform multiple protective functions against different HPV strains.
Solution Approach 2:
The patent merges the L1 protein sequences of different HPV types by substituting specific segments (amino acid positions 269-288 and 347-358) with homologous segments from other HPV types. This merging creates a unified chimeric protein structure that retains the ability to self-assemble into VLPs while presenting multiple type-specific neutralizing epitopes.
2Adaptability or versatility
If multiple HPV types are included in vaccines to broaden protection range, then the protection range is improved, but production cost increases
Solution Approach 1:
The chimeric L1 protein serves as a universal vaccine component that provides protection against multiple HPV types through a single production process. By encoding all necessary epitopes from HPV39, HPV68, and HPV70 in one protein sequence, the vaccine can be manufactured as a single product rather than requiring separate production and formulation of multiple type-specific VLPs.
Solution Approach 2:
The patent combines multiple HPV type sequences into a single chimeric L1 protein that can be expressed and purified in one manufacturing batch. This merging eliminates the need for separate production lines, quality control processes, and formulation steps for each HPV type, significantly reducing manufacturing complexity and cost.
3Adaptability or versatility
If multiple HPV types are included in vaccines to broaden protection range, then the protection range is improved, but safety concerns increase
Solution Approach 1:
The chimeric L1 protein provides a safer alternative by inducing cross-protective immunity through a single immunizing agent. Instead of administering multiple type-specific VLPs that could cause cumulative immune reactions or require multiple injections, the chimeric protein delivers multiple protective epitopes in one dose, reducing the total immunizing burden and potential safety risks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutated HPV39 L1 protein offers significant cross-protection against HPV39 and other types like HPV68 and HPV70, effectively preventing infections and associated diseases such as cervical cancer and condyloma acuminatum, while reducing the complexity and cost of vaccine production.
Implementation Method 1
Major capsid protein L1 of HPV has the characteristic of self-assembling into hollow Virus-Like Particle (VLP)
Implementation Method 2
HPV VLP is highly similar to natural HPV in terms of structure, retains most of the neutralizing epitopes of natural virus, and can induce the generation of high-titer neutralizing antibodies
Data Source
AI summary
The invention relates to a mutated HPV39 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV39 and HPV68, or HPV39, HPV68 and HPV70), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.